# The Effects of RVX000222 on Glucose Metabolism in Individuals With Pre-diabetes

> **NCT01728467** · PHASE2 · COMPLETED · sponsor: **Resverlogix Corp** · enrollment: 20 (actual)

## Conditions studied

- Diabetes

## Interventions

- **DRUG:** RVX000222
- **DRUG:** Placebo, RVX000222

## Key facts

- **NCT ID:** NCT01728467
- **Lead sponsor:** Resverlogix Corp
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2014-03
- **Final completion:** 2014-03
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2014-04-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01728467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01728467, "The Effects of RVX000222 on Glucose Metabolism in Individuals With Pre-diabetes". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01728467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*